Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Anne Hickman, Jennifer Hibma, Hoi-Kei Lon, Joseph Piscitelli, Pooneh Soltantabar, Diane Wang, Sibo Jiang, Gregory Finn, Akos Czibere

Blood (2022) 140 (Supplement 1): 7174–7175.

https://doi.org/10.1182/blood-2022-169971

Published: 2022

Journal Articles

Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study

Marcos J.G. de Lima, Partow Kebriaei, Francesco Lanza, Christina Cho, Gizelle Popradi, Michael T Hemmer, Mei-Jie Zhang, Fan Zhang, Richa Shah, Verna Welch, Saara Tikka, Erik Vandendries, Matthias Stelljes, David I. Marks, Wael Saber

Blood (2022) 140 (Supplement 1): 6023–6025.

https://doi.org/10.1182/blood-2022-160315

Published: 2022

Journal Articles

The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study

Muhit Özcan, Ryan D. Cassaday, Pawan Singh, Ewa Zarzycka, Xin Zhang, Eric Nègre, Erik Vandendries, Fevzi Altuntas

Blood (2021) 138 (Supplement 1): 1208.

https://doi.org/10.1182/blood-2021-150001

Published: 2021

Journal Articles

Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Partow Kebriaei, MD, Daniel J. DeAngelo, MD, Anjali S. Advani, MD, Susan M. O'Brien, MD, David Marks, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Tao Wang, Erik Vandendries, MD PhD, A. Douglas Laird, PhD, Sonja Nick, MSc, Matthias Stelljes, MD

Blood (2018) 132 (Supplement 1): 4031.

https://doi.org/10.1182/blood-2018-99-110552

Published: 2018

Journal Articles

Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, Katherine F Liau, Kevin Nguyen, Barbara Sleight, Erik Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, Anjali S. Advani, MD

Blood (2018) 132 (Supplement 1): 2699.

https://doi.org/10.1182/blood-2018-99-110826

Published: 2018

Journal Articles

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, PhD, Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, MD PhD, A. Douglas Laird, Anjali S. Advani, MD

Blood (2017) 130 (Supplement 1): 1272.

https://doi.org/10.1182/blood.V130.Suppl_1.1272.1272

Published: 2017

Journal Articles

Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study

Hagop M. Kantarjian, MD, Daniel J. DeAngelo, MD, Matthias Stelljes, MD, Michaela Liedtke, MD, Wendy Stock, MD, Nicola Goekbuget, MD, Susan M. O'Brien, MD, Elias J. Jabbour, MD, Tao Wang, PhD, Jane Liang White, ScD, Barbara Sleight, Erik Vandendries, MD PhD, Anjali S. Advani, MD

Blood (2017) 130 (Supplement 1): 2574.

https://doi.org/10.1182/blood.V130.Suppl_1.2574.2574

Published: 2017

Journal Articles

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Partow Kebriaei, MD, Matthias Stelljes, MD, Daniel J. DeAngelo, MD, Nicola Goekbuget, MD, Hagop M. Kantarjian, MD, Anjali S. Advani, MD, Akil Merchant, MD, Wendy Stock, MD, Tao Wang, PhD, Hui Zhang, Fausto Loberiza, Erik Vandendries, MD PhD, David Marks

Blood (2017) 130 (Supplement 1): 886.

https://doi.org/10.1182/blood.V130.Suppl_1.886.886

Published: 2017

Journal Articles

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

Anjali S. Advani, MD, Elias J. Jabbour, MD, Matthias Stelljes, MD, Wendy Stock, MD, Michaela Liedtke, MD, Nicola Goekbuget, MD, Susan M. O'Brien, MD, Jane Liang White, ScD, Tao Wang, PhD, A. Douglas Laird, PhD, Erik Vandendries, MD PhD, Hagop M. Kantarjian, MD

Blood (2017) 130 (Supplement 1): 2557.

https://doi.org/10.1182/blood.V130.Suppl_1.2557.2557

Published: 2017

Journal Articles

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Matthias Stelljes, MD, Yun Su, MD MPH, MS, Kyle Fahrbach, PhD, Erik Vandendries, MD PhD, Veronique Page, M.Sc, Uchenna Onyekwere, MD MPh, Yunyang Wang, M.Sc, M.Pharm, Joseph C. Cappelleri, PhD MPH, MS, Irina Proskorovsky, M.Sc

Blood (2017) 130 (Supplement 1): 2558.

https://doi.org/10.1182/blood.V130.Suppl_1.2558.2558

Published: 2017

Journal Articles

Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase

Anjali S. Advani, MD, Elias J. Jabbour, MD, Matthias Stelljes, Daniel J. DeAngelo, MD PhD, Michaela Liedtke, MD, Wendy Stock, MD, Nicola Gökbuget, MD, Susan O'Brien, MD, Kongming Wang, PhD, Tao Wang, PhD, M. Luisa Paccagnella, PhD, Barbara Sleight, MD, Erik Vandendries, MD PhD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 5188.

https://doi.org/10.1182/blood.V128.22.5188.5188

Published: 2016

Journal Articles

A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage

Anjali S. Advani, MD, Anthony S. Stein, MD, Hagop M. Kantarjian, MD, Andrei R. Shustov, MD, Daniel J. DeAngelo, MD PhD, Revathi Ananthakrishnan, Katherine Liau, Erik Vandendries, MD, Wendy Stock, MD

Blood (2014) 124 (21): 2255.

https://doi.org/10.1182/blood.V124.21.2255.2255

Published: 2014

Journal Articles

Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Daniel J. DeAngelo, MD, Ph.D, Wendy Stock, M.D., Andrei R. Shustov, MD, Michaela Liedtke, MD, Charles A. Schiffer, MD, Revathi Ananthakrishnan, Joseph P. Boni, PhD, Kenneth Luu, Katherine Liau, Erik Vandendries, MD, Anjali S. Advani, MD

Blood (2013) 122 (21): 3906.

https://doi.org/10.1182/blood.V122.21.3906.3906

Published: 2013

Journal Articles

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Randeep Sangha, Andrew Davies, PhD, Nam H. Dang, MD, PhD, Michinori Ogura, MD, PhD, David A. MacDonald, MD, Angela Volkert, Revathi Ananthakrishnan, Kenneth Luu, Joseph P. Boni, PhD, Erik Vandendries, MD, Yeow-Tee YT Goh, MD

Blood (2013) 122 (21): 1821.

https://doi.org/10.1182/blood.V122.21.1821.1821

Published: 2013

Journal Articles

An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data

Michinori Ogura, MD, PhD, Kiyohiko Hatake, Andrew Davies, MD, Michael Crump, MD, FRCPC, Kensei Tobinai, MD, PhD, Mitchell R Smith, MD, PhD, Fritz Offner, Shaw-Ling Wang, Taro Ishibashi, Luisa Paccagnella, Erik Vandendries, David A MacDonald

Blood (2012) 120 (21): 1633.

https://doi.org/10.1182/blood.V120.21.1633.1633

Published: 2012

Journal Articles

Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.

Daniel DeAngelo, MD, Wendy Stock, MD, Stephen Petersdorf, MD, Shaw-Ling Wang, Angela Volkert, Erik Vandendries, Anjali Advani, MD

Blood (2012) 120 (21): 2612.

https://doi.org/10.1182/blood.V120.21.2612.2612

Published: 2012

NARROW

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study

The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study

Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study

Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level

Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status

Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)

Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase

A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage

Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data

Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only